Cargando…

Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma

Tumor microenvironment and host immunity are closely related to outcome in patients with mantle cell lymphoma (MCL). However, few researchers have focused on the prognostic value of peripheral blood lymphocyte subsets counts. The purpose of this study was to investigate the prognostic value of lymph...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin‐Yu, Xu, Ji, Zhu, Hua‐Yuan, Wang, Yan, Wang, Li, Fan, Lei, Wu, Yu‐Jie, Li, Jian‐Yong, Xu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084668/
https://www.ncbi.nlm.nih.gov/pubmed/27465799
http://dx.doi.org/10.1111/cas.13020
_version_ 1782463431122616320
author Zhang, Xin‐Yu
Xu, Ji
Zhu, Hua‐Yuan
Wang, Yan
Wang, Li
Fan, Lei
Wu, Yu‐Jie
Li, Jian‐Yong
Xu, Wei
author_facet Zhang, Xin‐Yu
Xu, Ji
Zhu, Hua‐Yuan
Wang, Yan
Wang, Li
Fan, Lei
Wu, Yu‐Jie
Li, Jian‐Yong
Xu, Wei
author_sort Zhang, Xin‐Yu
collection PubMed
description Tumor microenvironment and host immunity are closely related to outcome in patients with mantle cell lymphoma (MCL). However, few researchers have focused on the prognostic value of peripheral blood lymphocyte subsets counts. The purpose of this study was to investigate the prognostic value of lymphocyte subsets and absolute monocyte counts. Sixty‐eight patients were analyzed retrospectively. Absolute CD4(+) T cell counts (ACD4C), CD8(+) T cell counts, nature killer cell counts, and CD4/CD8 ratios were assessed by peripheral blood flow cytometry and correlated with clinical parameters and long‐term outcomes. The median follow‐up for all patients was 21 months and the median survival time was 44 months. The overall survival (OS) rate at 1, 3, and 5 years was 80%, 51%, and 41%, respectively. In our cohort, high absolute monocyte count, and low ACD4C and CD4/CD8 ratio were associated with unfavorable OS (P = 0.029, P = 0.027, and P = 0.045, respectively) by univariate analysis. Multivariate analysis indicated that low ACD4C was a significant predictor of unfavorable OS (P = 0.004) independent of the simplified MCL International Prognostic Index (P = 0.048) in patients treated with or without rituximab (P = 0.011). Low CD4(+) T cell counts proved to be a significant predictor of unfavorable OS in patients with MCL.
format Online
Article
Text
id pubmed-5084668
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50846682016-10-31 Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma Zhang, Xin‐Yu Xu, Ji Zhu, Hua‐Yuan Wang, Yan Wang, Li Fan, Lei Wu, Yu‐Jie Li, Jian‐Yong Xu, Wei Cancer Sci Original Articles Tumor microenvironment and host immunity are closely related to outcome in patients with mantle cell lymphoma (MCL). However, few researchers have focused on the prognostic value of peripheral blood lymphocyte subsets counts. The purpose of this study was to investigate the prognostic value of lymphocyte subsets and absolute monocyte counts. Sixty‐eight patients were analyzed retrospectively. Absolute CD4(+) T cell counts (ACD4C), CD8(+) T cell counts, nature killer cell counts, and CD4/CD8 ratios were assessed by peripheral blood flow cytometry and correlated with clinical parameters and long‐term outcomes. The median follow‐up for all patients was 21 months and the median survival time was 44 months. The overall survival (OS) rate at 1, 3, and 5 years was 80%, 51%, and 41%, respectively. In our cohort, high absolute monocyte count, and low ACD4C and CD4/CD8 ratio were associated with unfavorable OS (P = 0.029, P = 0.027, and P = 0.045, respectively) by univariate analysis. Multivariate analysis indicated that low ACD4C was a significant predictor of unfavorable OS (P = 0.004) independent of the simplified MCL International Prognostic Index (P = 0.048) in patients treated with or without rituximab (P = 0.011). Low CD4(+) T cell counts proved to be a significant predictor of unfavorable OS in patients with MCL. John Wiley and Sons Inc. 2016-09-14 2016-10 /pmc/articles/PMC5084668/ /pubmed/27465799 http://dx.doi.org/10.1111/cas.13020 Text en © 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Zhang, Xin‐Yu
Xu, Ji
Zhu, Hua‐Yuan
Wang, Yan
Wang, Li
Fan, Lei
Wu, Yu‐Jie
Li, Jian‐Yong
Xu, Wei
Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
title Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
title_full Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
title_fullStr Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
title_full_unstemmed Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
title_short Negative prognostic impact of low absolute CD4(+) T cell counts in peripheral blood in mantle cell lymphoma
title_sort negative prognostic impact of low absolute cd4(+) t cell counts in peripheral blood in mantle cell lymphoma
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084668/
https://www.ncbi.nlm.nih.gov/pubmed/27465799
http://dx.doi.org/10.1111/cas.13020
work_keys_str_mv AT zhangxinyu negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT xuji negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT zhuhuayuan negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT wangyan negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT wangli negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT fanlei negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT wuyujie negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT lijianyong negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma
AT xuwei negativeprognosticimpactoflowabsolutecd4tcellcountsinperipheralbloodinmantlecelllymphoma